PMID- 28130771
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 8
IP  - 2
DP  - 2017 Apr
TI  - Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, 
      Double-blind, Controlled Crossover Trial.
PG  - 293-307
LID - 10.1007/s13300-017-0226-y [doi]
AB  - INTRODUCTION: The alpha-glucosidase inhibitor acarbose is an efficacious medicine for 
      the treatment and prevention of type 2 diabetes mellitus (T2DM). However, the 
      response of gut microbiota to acarbose is important, as the microbiota may have a 
      critical role in the development of metabolic diseases, and acarbose is 
      metabolized exclusively within the gastrointestinal tract. We explored the 
      changes in the proportion and diversity of gut microbiota before and after 
      treatment with acarbose in patients with prediabetes. METHODS: We designed a 
      randomized, double-blind, controlled crossover trial in which 52 Chinese patients 
      with prediabetes by an oral glucose tolerance test (OGTT) with a BMI of 
      18-35 kg/m(2) were randomly allocated to treatment with acarbose or placebo. Gut 
      microbiota characterizations were determined with 16S rDNA-based high-throughput 
      sequencing. RESULTS: Of the 52 participants who entered the study, 40 (76.9%) 
      completed the protocol. On the basis of the operational taxonomic unit (OTU) 
      profiles, a total of 107 OTUs were significantly altered after acarbose 
      treatment, with 76 (71%) assigned to the order of Clostridiales. Ruminococcaceae 
      (15 OTUs) and Lachnospiraceae (22 OTUs) decreased in response to acarbose, and 48 
      OTUs increased by 12.8-fold, including Lactobacillaceae (8 of 9 belonging to 
      Lactobacillus), Ruminococcaceae (6 of 11 belonging to Faecalibacterium), and 
      Veillonellaceae (8 of 15 belonging to Dialister). At genera level, five 
      flourished after treatment with acarbose, including Lactobacillus and Dialister, 
      while Butyricicoccus, Phascolarctobacterium, and Ruminococcus were inhibited. 
      CONCLUSION: This study suggests that the benefits of acarbose for T2DM may 
      correlate with the selective modulation of the gut microbiota. TRIAL 
      REGISTRATION: Chinese Clinical Trial Register number, ChiCTR-TTRCC-13004112.
FAU - Zhang, Xiuying
AU  - Zhang X
AD  - Department of Endocrinology and Metabolism, Peking University People's Hospital, 
      Peking University Diabetes Centre, Beijing, 100044, China.
FAU - Fang, Zhiwei
AU  - Fang Z
AD  - Institute for Systems Biology, Jianghan University, Wuhan, 430056, China.
FAU - Zhang, Chunfang
AU  - Zhang C
AD  - Department of Clinical Epidemiology, Peking University People's Hospital, 
      Beijing, 100044, China.
FAU - Xia, Huihua
AU  - Xia H
AD  - BGI-Shenzhen, Shenzhen, 518083, China.
FAU - Jie, Zhuye
AU  - Jie Z
AD  - BGI-Shenzhen, Shenzhen, 518083, China.
FAU - Han, Xueyao
AU  - Han X
AD  - Department of Endocrinology and Metabolism, Peking University People's Hospital, 
      Peking University Diabetes Centre, Beijing, 100044, China.
FAU - Chen, Yingli
AU  - Chen Y
AD  - Department of Endocrinology and Metabolism, Peking University People's Hospital, 
      Peking University Diabetes Centre, Beijing, 100044, China.
FAU - Ji, Linong
AU  - Ji L
AD  - Department of Endocrinology and Metabolism, Peking University People's Hospital, 
      Peking University Diabetes Centre, Beijing, 100044, China. jiln@bjmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170127
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5380489
OTO - NOTNLM
OT  - Acarbose
OT  - Cardiovascular disease
OT  - Gut microflora
OT  - Prediabetes
OT  - Type 2 diabetes
EDAT- 2017/01/29 06:00
MHDA- 2017/01/29 06:01
PMCR- 2017/01/27
CRDT- 2017/01/29 06:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/01/29 06:00 [pubmed]
PHST- 2017/01/29 06:01 [medline]
PHST- 2017/01/29 06:00 [entrez]
PHST- 2017/01/27 00:00 [pmc-release]
AID - 10.1007/s13300-017-0226-y [pii]
AID - 226 [pii]
AID - 10.1007/s13300-017-0226-y [doi]
PST - ppublish
SO  - Diabetes Ther. 2017 Apr;8(2):293-307. doi: 10.1007/s13300-017-0226-y. Epub 2017 
      Jan 27.